NBT Bank N.A. Buys 102,588 Shares of Johnson & Johnson $JNJ

Key Points

• NBT Bank bought 102,588 Johnson & Johnson shares worth approximately $27.2 million, making J&J its 10th-largest holding. Institutional investors and hedge funds own 69.55% of the stock.
• Analysts maintain a consensus “Moderate Buy” rating with a $275.92 average price target, although Johnson Rice and Erste Group downgraded the shares to “Hold.”
• J&J exceeded quarterly earnings expectations and reported 5.9% year-over-year revenue growth, while declaring a $1.34 quarterly dividend, equivalent to a 2.0% yield.

NBT Bank N.A. bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 102,588 shares of the company's stock, valued at approximately $27,159,000. Johnson & Johnson accounts for 1.8% of NBT Bank N.A.'s holdings, making the stock its 10th biggest holding.

A number of other hedge funds have also recently added to or reduced their stakes in the business. National Pension Service grew its holdings in shares of Johnson & Johnson by 1.3% during the 2nd quarter. National Pension Service now owns 5,226,968 shares of the company's stock worth $1,327,493,000 after purchasing an additional 67,484 shares during the period. IFP Advisors Inc increased its position in Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B raised its holdings in Johnson & Johnson by 9.8% in the second quarter. Elefante Mark B now owns 28,686 shares of the company's stock valued at $7,285,000 after buying an additional 2,563 shares during the period. Gradient Investments LLC raised its holdings in Johnson & Johnson by 9.9% in the second quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock valued at $38,815,000 after buying an additional 13,737 shares during the period. Finally, Louisiana State Employees Retirement System acquired a new position in Johnson & Johnson during the first quarter valued at approximately $30,017,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on JNJ shares. Evercore set a $300.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Johnson Rice downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday. Argus set a $300.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 29th. TD Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Finally, Erste Group Bank downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Insider Activity

In related news, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president directly owned 16,994 shares in the company, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $264.13 on Monday. The stock's 50 day moving average price is $265.64 and its 200 day moving average price is $250.28. The firm has a market capitalization of $635.85 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 2.61 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. Johnson & Johnson has a one year low of $184.66 and a one year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The firm had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the prior year, the business earned $2.80 EPS. Johnson & Johnson's quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio is 81.21%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J's oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.